HeartGenetics launches new test in Oncology

2017-07-03

HeartGenetics continues to increase its portfolio of genetic tests, particularly within the pharmacogenetics area. OncoAlvo® is a new genetic study of the anti-EGFR antibody therapy response in metastatic colorectal carcinoma. With this new test, medical oncologists will be able to know what is the best and most effective treatment for each patient.